BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

April 9, 2012 7:00 AM UTC

Actelion Ltd. (SIX:ATLN) was up CHF0.36 to CHF33.36 last week after Japan's Ministry of Health, Labor and Welfare (MHLW) approved Brazaves miglustat to treat Niemann-Pick type C disease.

Separately, Actelion discontinued development of setipiprant. The biotech said data from a Phase III trial in seasonal allergic rhinitis (SAR) and a Phase IIb trial in asthma "did not confirm efficacy findings made in earlier studies." Actelion said it will now focus on development of a "more potent" follow-up compound that is in Phase I (see B16)...